Histone

Sepsis Drug Pipeline Research Report 2024: Insights from 30 Companies and 35 Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024
Pharmaceutical, Health, Clinical Trials, Therapy, Acquisition, Blood pressure, HBV, HCV, Hepatitis B virus, Heparin, CRISPR, Infection, Escherichia coli, Melanoma, News, Cancer, Liver cancer, Discovery, Cell, Vaccine, Intensive care medicine, Adrenomedullin, ADM, COVID, Fungal infection, Patient, Protein, Clinical trial, Survival, Endothelium, NDA, Histone, Thymosin

This report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Sepsis pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Sepsis pipeline landscape.
  • A detailed picture of the Sepsis pipeline landscape is provided which includes the disease overview and Sepsis treatment guidelines.
  • This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sepsis drugs.

Kanazawa University research: Chromatin Accessibility: A new avenue for gene editing

Retrieved on: 
Friday, February 16, 2024
Nucleosome, ATAC, Kanazawa University, CRISPR, Gene editing, Stem cell, B cell, TFDP1, Genome, Digital selective calling, Protein, Gene, Histone, DNA, Running, Chromatin, Vaccine

KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.

Key Points: 
  • KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.
  • This phenomenon known as 'chromatin accessibility' involves a privileged set of protein molecules, many of which are still unknown.
  • Now, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, led by Yusuke Miyanari, have used advanced genetic screening methods to unravel chromatin accessibility and its pathways.
  • In this study the genes identified by CRISPR screening were subjected to ATAC-see to confirm their involvement with chromatin accessibility.

Kanazawa University research: Chromatin Accessibility: A new avenue for gene editing

Retrieved on: 
Friday, February 16, 2024
Nucleosome, ATAC, Kanazawa University, CRISPR, Gene editing, Stem cell, B cell, TFDP1, Genome, Digital selective calling, Protein, Gene, Histone, DNA, Running, Chromatin, Vaccine

KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.

Key Points: 
  • KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.
  • This phenomenon known as 'chromatin accessibility' involves a privileged set of protein molecules, many of which are still unknown.
  • Now, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, led by Yusuke Miyanari, have used advanced genetic screening methods to unravel chromatin accessibility and its pathways.
  • In this study the genes identified by CRISPR screening were subjected to ATAC-see to confirm their involvement with chromatin accessibility.

Groundbreaking Results Using Canady Helios™ Cold Plasma Treatment Published in MDPI Journal “Cancers”

Retrieved on: 
Wednesday, August 2, 2023
Research, Technology, Medical Devices, Surgery, Health Technology, Biotechnology, Robotics, Health, Science, Oncology, Canady, Cell death, RNS, Histone, Survival, Clinical trial, Immunotherapy, CHCP, Irreversible electroporation, Plasma, ROS, Cancer, LRR, Patient, Sheba Medical Center, Reactive oxygen species, Apoptosis, Education minister, Cell division, FACS, Neoplasm, Rush University Medical Center, Recurrence, FDA, Reactive nitrogen species, Messenger, Pharmaceutical industry

It is estimated that 65% of solid tumor resections result in residual microscopic tumor cells at the surgical margin, which contributes to LRR and poor survival rates.

Key Points: 
  • It is estimated that 65% of solid tumor resections result in residual microscopic tumor cells at the surgical margin, which contributes to LRR and poor survival rates.
  • The recent trial reveals that treating the surgical margin following a tumorectomy significantly reduced local recurrence and increased overall survival.
  • CHCP opens a new and promising treatment for addressing the challenges of eradicating microscopic residual cancer cells following surgical tumor resection.
  • Jerome Canady, M.D., FACS, CEO stated, “We are very pleased to have our results published in the peer reviewed journal 'Cancers'.

HiStone's LUNA X HK568/HK568U: The Game-Changing POS Solution Redefining Retail and Hospitality Experiences

Retrieved on: 
Wednesday, June 28, 2023
Rotation, POS, Business, Central processing unit, Sale, Histone, LATAM, Mobile phone, Online shopping

QINGDAO, China, June 28, 2023 /PRNewswire/ -- HiStone, a leading provider of innovative POS and Self-Checkout hardware solutions, announces the release of its latest addition to the LUNA X model range, the HK568/HK568U. This all-in-one POS model sets new standards in performance, flexibility, and user experience, solidifying HiStone's position as a reliable and premium-quality technology vendor in the industry.

Key Points: 
  • HiStone reveals LUNA X HK568/HK568U, an all-in-one point-of-sale (POS) model revolutionizing the retail and hospitality industries
    QINGDAO, China, June 28, 2023 /PRNewswire/ -- HiStone, a leading provider of innovative POS and Self-Checkout hardware solutions, announces the release of its latest addition to the LUNA X model range, the HK568/HK568U.
  • This all-in-one POS model sets new standards in performance, flexibility, and user experience, solidifying HiStone's position as a reliable and premium-quality technology vendor in the industry.
  • This enhanced processing capability empowers retailers and hospitality providers to handle complex operations efficiently, ensuring frictionless payment services for their customers.
  • With the launch of the HK568/HK568U, HiStone once again demonstrates its commitment to driving digital transformation and supporting businesses in the retail and hospitality sectors.

HiStone's LUNA X HK568/HK568U: The Game-Changing POS Solution Redefining Retail and Hospitality Experiences

Retrieved on: 
Wednesday, June 28, 2023
Rotation, POS, Business, Central processing unit, Sale, Histone, Mobile phone, Online shopping

QINGDAO, China, June 28, 2023 /PRNewswire/ -- HiStone, a leading provider of innovative POS and Self-Checkout hardware solutions, announces the release of its latest addition to the LUNA X model range, the HK568/HK568U. This all-in-one POS model sets new standards in performance, flexibility, and user experience, solidifying HiStone's position as a reliable and premium-quality technology vendor in the industry.

Key Points: 
  • HiStone reveals LUNA X HK568/HK568U, an all-in-one point-of-sale (POS) model revolutionizing the retail and hospitality industries
    QINGDAO, China, June 28, 2023 /PRNewswire/ -- HiStone, a leading provider of innovative POS and Self-Checkout hardware solutions, announces the release of its latest addition to the LUNA X model range, the HK568/HK568U.
  • This all-in-one POS model sets new standards in performance, flexibility, and user experience, solidifying HiStone's position as a reliable and premium-quality technology vendor in the industry.
  • This enhanced processing capability empowers retailers and hospitality providers to handle complex operations efficiently, ensuring frictionless payment services for their customers.
  • With the launch of the HK568/HK568U, HiStone once again demonstrates its commitment to driving digital transformation and supporting businesses in the retail and hospitality sectors.

HiStone's LUNA X HK568/HK568U: The Game-Changing POS Solution Redefining Retail and Hospitality Experiences

Retrieved on: 
Wednesday, June 28, 2023
Rotation, POS, Central processing unit, Sale, Histone, Mobile phone, Online shopping

QINGDAO, China, June 28, 2023 /PRNewswire/ -- HiStone, a leading provider of innovative POS and Self-Checkout hardware solutions, announces the release of its latest addition to the LUNA X model range, the HK568/HK568U. This all-in-one POS model sets new standards in performance, flexibility, and user experience, solidifying HiStone's position as a reliable and premium-quality technology vendor in the industry.

Key Points: 
  • HiStone reveals LUNA X HK568/HK568U, an all-in-one point-of-sale (POS) model revolutionizing the retail and hospitality industries
    QINGDAO, China, June 28, 2023 /PRNewswire/ -- HiStone, a leading provider of innovative POS and Self-Checkout hardware solutions, announces the release of its latest addition to the LUNA X model range, the HK568/HK568U.
  • This all-in-one POS model sets new standards in performance, flexibility, and user experience, solidifying HiStone's position as a reliable and premium-quality technology vendor in the industry.
  • This enhanced processing capability empowers retailers and hospitality providers to handle complex operations efficiently, ensuring frictionless payment services for their customers.
  • With the launch of the HK568/HK568U, HiStone once again demonstrates its commitment to driving digital transformation and supporting businesses in the retail and hospitality sectors.

HiStone's LUNA X HK568/HK568U: The Game-Changing POS Solution Redefining Retail and Hospitality Experiences

Retrieved on: 
Wednesday, June 28, 2023
Rotation, POS, Business, Central processing unit, Sale, Histone, Mobile phone, Online shopping

QINGDAO, China, June 28, 2023 /PRNewswire/ -- HiStone, a leading provider of innovative POS and Self-Checkout hardware solutions, announces the release of its latest addition to the LUNA X model range, the HK568/HK568U. This all-in-one POS model sets new standards in performance, flexibility, and user experience, solidifying HiStone's position as a reliable and premium-quality technology vendor in the industry.

Key Points: 
  • HiStone reveals LUNA X HK568/HK568U, an all-in-one point-of-sale (POS) model revolutionizing the retail and hospitality industries
    QINGDAO, China, June 28, 2023 /PRNewswire/ -- HiStone, a leading provider of innovative POS and Self-Checkout hardware solutions, announces the release of its latest addition to the LUNA X model range, the HK568/HK568U.
  • This all-in-one POS model sets new standards in performance, flexibility, and user experience, solidifying HiStone's position as a reliable and premium-quality technology vendor in the industry.
  • This enhanced processing capability empowers retailers and hospitality providers to handle complex operations efficiently, ensuring frictionless payment services for their customers.
  • With the launch of the HK568/HK568U, HiStone once again demonstrates its commitment to driving digital transformation and supporting businesses in the retail and hospitality sectors.

HiStone's LUNA X HK568/HK568U: The Game-Changing POS Solution Redefining Retail and Hospitality Experiences

Retrieved on: 
Wednesday, June 28, 2023
Rotation, POS, Business, Central processing unit, Sale, Histone, Mobile phone, Online shopping, EU

QINGDAO, China, June 28, 2023 /PRNewswire/ -- HiStone, a leading provider of innovative POS and Self-Checkout hardware solutions, announces the release of its latest addition to the LUNA X model range, the HK568/HK568U. This all-in-one POS model sets new standards in performance, flexibility, and user experience, solidifying HiStone's position as a reliable and premium-quality technology vendor in the industry.

Key Points: 
  • HiStone reveals LUNA X HK568/HK568U, an all-in-one point-of-sale (POS) model revolutionizing the retail and hospitality industries
    QINGDAO, China, June 28, 2023 /PRNewswire/ -- HiStone, a leading provider of innovative POS and Self-Checkout hardware solutions, announces the release of its latest addition to the LUNA X model range, the HK568/HK568U.
  • This all-in-one POS model sets new standards in performance, flexibility, and user experience, solidifying HiStone's position as a reliable and premium-quality technology vendor in the industry.
  • This enhanced processing capability empowers retailers and hospitality providers to handle complex operations efficiently, ensuring frictionless payment services for their customers.
  • With the launch of the HK568/HK568U, HiStone once again demonstrates its commitment to driving digital transformation and supporting businesses in the retail and hospitality sectors.

Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on "Patient-Proposed Healthcare Services" System

Retrieved on: 
Monday, April 3, 2023
Insurance, Clinical trial, Cancer, National Cancer Institute, AYA, Government, Eisai, Histone, National Cancer Center, Patient, Standard of care, Health, Growth, Safety, EZH2, Adolescence, Pharmaceutical industry, Ipsen

TOKYO, Apr 3, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement with the National Cancer Center to collaborate on investigator-initiated clinical research for the EZH2 inhibitor tazemetostat hydrobromide (generic name, product name "Tazverik Tablets 200 mg", "tazemetostat") based on "Patient-Proposed Healthcare Services" system.

Key Points: 
  • TOKYO, Apr 3, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement with the National Cancer Center to collaborate on investigator-initiated clinical research for the EZH2 inhibitor tazemetostat hydrobromide (generic name, product name "Tazverik Tablets 200 mg", "tazemetostat") based on "Patient-Proposed Healthcare Services" system.
  • This clinical research will be conducted by the National Cancer Center Hospital.
  • Researched and developed by Eisai and Epizyme, Inc.,** an Ipsen (Headquarters: France) company, tazemetostat is a first-in-class, oral small molecule inhibitor of the epigenetic enzyme EZH2.
  • Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer.